Eli Lilly and Company increased its U.S. revenue by 15% for the fourth-quarter, but the rise may have come partly at the expense of patients with diabetes.
About Erica Mitchell
This author has yet to write their bio.Meanwhile lets just say that we are proud Erica Mitchell contributed a whooping 220 entries.
Entries by Erica Mitchell
Injectable insulin, which keeps some diabetics alive and keeps others out of serious health crises, has soared in price in the last few years.
Competition among generic drug makers pushes drug prices downward.
The cost of management of complications from diabetes in the USA amounted to US$263 billion (about £171 billion) in 2013, up from $92 billion (about £60 billion) in 2002.
Insulin is a vital medicine for patients with diabetes mellitus. Newer, more expensive insulin products and the lack of generic insulins in the United States have increased costs for patients and insurers.
In 2012, an estimated 29 million individuals, or 9.3% of the US population, had diabetes, with 30.8% of these patients using insulin.
An essential drug that has been on the market for decades still has a sticker price out of range for some patients who need it.
To assess the cost implications of diabetes prevention, it is important to know the lifetime medical cost of people with diabetes relative to those without.
Insulin analogs are molecularly altered forms of insulin. Compared with human synthetic and animal insulin for treatment of type 2 diabetes, short-acting analogs may offer flexible dosing and convenience, long-acting analogs less nocturnal hypoglycemia, but both at greater cost.
This study updates previous estimates of the economic burden of diagnosed diabetes and quantifies the increased health resource use and lost productivity associated with diabetes in 2012.